share_log

HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target

Benzinga ·  Oct 12, 2023 07:18

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment